FDA Approves Lisraya (brepocitinib) for the Treatment of Adults with Dermatomyositis
RegulatoryapprovedLisrayaPositive
AI Analysis
Summary
The FDA has approved Lisraya (brepocitinib) 30 mg for treating adults with dermatomyositis, marking a significant regulatory milestone for Roivant.
Outcome Details
FDA approved Lisraya (brepocitinib) 30 mg for the treatment of adults with dermatomyositis
Importance:8/10
Sentiment:
0.90
FDA approvalLisrayabrepocitinibdermatomyositisRoivant
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on August 27, 2026 9:08 PM